• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Announces Board Expansion and Changes

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MDRX alert in real time by email

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors

    Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives.

    As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silverman, effective February 20, 2025. The Company will also identify two additional independent directors to join the Board, subject to Kent Lake's approval; one will be appointed by March 22, 2025, and the other will be appointed promptly following the filing of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2022 (the "2022 Form 10-K").

    On February 14, 2025, Jonathan Judge stepped down from the Board, effective immediately, and Chairman Greg Garrison will retire from the Board shortly following the filing of the 2022 Form 10-K.

    Vinit Asar is the former Chief Executive Officer ("CEO") of Hanger, Inc. ("Hanger") and brings 30 years of diversified global healthcare leadership experience in medical services and non-acute healthcare services. While CEO of Hanger, he grew revenue from $700 million to $1.4 billion via organic and inorganic growth combined with strategic divestitures and business exits. He also significantly strengthened Hanger's infrastructure, leadership team and governance while navigating a financial restatement and NYSE delisting process. He currently serves as the Executive Chairman of Hanger, which was taken private in 2022, and on the board of directors of ZimVie Inc. (NASDAQ:ZIMV).

    Louis Silverman is a seasoned healthcare executive currently serving as Chairman and CEO of Hicuity Health, the nation's largest provider of 24x7 high acuity telemedicine services. He brings over 30 years of leadership experience in health information technology and technology-enabled healthcare services. Mr. Silverman previously served as the CEO of Quality Systems (NASDAQ:QSII), a leader in the ambulatory electronic healthcare record market. Silverman also served as CEO of Marina Medical, a specialty revenue cycle management company. He currently serves on the board of directors of Oncocyte Corporation (NASDAQ:OCX).

    "We appreciate our stockholders' efforts to put forth well-qualified individuals to serve on the Board," stated Greg Garrison, Chairman of the Board. "In parallel with ongoing refreshment planning, we are adding new independent directors with deep strategic planning, finance, healthcare and restatement experience to strengthen the Board as we focus on our priorities: executing our standalone strategy, becoming current in financial reporting and relisting our common stock."

    Mr. Garrison continued, "Jon has been an invaluable member of our Board for almost nine years, bringing exceptional leadership, insight, and dedication throughout his tenure. On behalf of the Board and the entire organization, I sincerely thank him for his perspective, partnership, and commitment to Veradigm. We wish him success in his future endeavors."

    "On behalf of the entire Veradigm team, I want to express our sincere gratitude to Greg, who has served as an important thought partner to management for nearly a decade. We are incredibly thankful for his guidance and leadership throughout his tenure, particularly in connection with the ongoing restatement," said Tom Langan, Interim Chief Executive Officer of Veradigm.

    Benjamin Natter, Managing Member of Kent Lake Capital, added, "We appreciate the constructive dialogue with the Board and management team and are pleased to have reached this agreement. As long-term investors, we believe that Veradigm is well positioned to deliver value to customers and the healthcare system while also generating attractive returns for shareholders. We believe these new directors will provide the right experience and perspective during this critical time."

    Kent Lake has agreed to abide by certain customary standstill commitments in connection with the Cooperation Agreement. The full Agreement will be filed by the Company with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K.

    About Veradigm®

    Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

    © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250220886186/en/

    Investors:

    Jenny Gelinas

    312-506-1237

    [email protected]

    Media:

    Concetta Rasiarmos

    630-740-3152

    [email protected]

    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX
    $OCX
    $ZIMV

    CompanyDatePrice TargetRatingAnalyst
    ZimVie Inc.
    $ZIMV
    4/10/2025$16.00Buy
    B. Riley Securities
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    ZimVie Inc.
    $ZIMV
    3/13/2025Buy → Hold
    Needham
    ZimVie Inc.
    $ZIMV
    5/16/2024$20.00Hold → Buy
    Needham
    Veradigm Inc.
    $MDRX
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    Veradigm Inc.
    $MDRX
    1/3/2024$11.00Equal Weight
    Barclays
    ZimVie Inc.
    $ZIMV
    11/16/2023Hold
    Needham
    Veradigm Inc.
    $MDRX
    7/6/2023Buy → Hold
    Argus
    More analyst ratings

    $MDRX
    $OCX
    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MDRX
    $OCX
    $ZIMV
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • ZimVie Announces Upcoming Changes to Company's Board of Directors

      PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

      3/13/25 4:15:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MDRX
    $OCX
    $ZIMV
    SEC Filings

    See more
    • SEC Form 10-Q filed by ZimVie Inc.

      10-Q - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:15:20 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • ZimVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - ZimVie Inc. (0001876588) (Filer)

      5/8/25 4:10:42 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      4/22/25 4:23:28 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    $OCX
    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by ZimVie Inc.

      SC 13G - ZimVie Inc. (0001876588) (Subject)

      11/14/24 4:11:11 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    $OCX
    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Langan Thomas covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.57% to 327,528 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      5/5/25 4:08:52 PM ET
      $MDRX
      EDP Services
      Technology
    • CEO Langan Thomas covered exercise/tax liability with 2,481 shares, decreasing direct ownership by 0.75% to 329,421 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      4/3/25 4:55:05 PM ET
      $MDRX
      EDP Services
      Technology
    • Officer Jamali Vafa converted options into 21,331 shares and covered exercise/tax liability with 9,333 shares, increasing direct ownership by 3% to 360,257 units (SEC Form 4)

      4 - ZimVie Inc. (0001876588) (Issuer)

      4/3/25 4:03:34 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $MDRX
    $OCX
    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on ZimVie with a new price target

      B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

      4/10/25 12:44:28 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • ZimVie downgraded by Needham

      Needham downgraded ZimVie from Buy to Hold

      3/13/25 7:58:34 AM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care

    $MDRX
    $OCX
    $ZIMV
    Financials

    Live finance-specific insights

    See more
    • ZimVie Reports First Quarter 2025 Financial Results

      Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

      5/8/25 4:05:00 PM ET
      $ZIMV
      Medical/Dental Instruments
      Health Care
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MDRX
    $OCX
    $ZIMV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care